Premium
Cisplatin‐based (PVB+M) chemotherapy in good‐risk and poor‐risk nonseminomatous germ cell tumors
Author(s) -
Saikia Tapan,
Hegde Upendra,
Advani Suresh,
Ramakrishnan Gopal,
Kulkarni Jagdeesh,
Desai Prafulla B.
Publication year - 1992
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930510207
Subject(s) - medicine , bleomycin , vinblastine , cisplatin , germ cell tumors , chemotherapy , surgery , induction chemotherapy , germinoma , risk factor , oncology
Twenty‐seven patients with metastatic nonseminomatous germ cell tumors were treated with Cisplatin, vinblastine, bleomycin, and low‐dose meth‐otrexate (PVB + M) combinations. Patients were divided into good‐risk and poor‐risk groups. All seven patients (100%) with good‐risk factors achieved complete response, and all are alive disease free at a median of 70 months. In the poor‐risk group, only 10 of 20 patients (50%) achieved complete response, and seven (35%) are alive disease free at a median of 58 months. Eight patients, 4 in each group, were required to undergo surgery for removal of postchemotherapy residual masses. The results confirm that Cisplatin‐based chemotherapy protocols are adequate to cure most patients with good‐risk factors, and newer approaches are needed for patients at poor risk. © 1992 Wiley‐Liss, Inc.